Biora Therapeutics Announces New Patents for its NaviCap™ Targeted Oral Delivery Platform
SAN DIEGO, June 28, 2023 (GLOBE NEWSWIRE) — Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech…
SAN DIEGO, June 28, 2023 (GLOBE NEWSWIRE) — Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech…
Former Awardee and Artelo Employee, Professor Saoirse O’Sullivan will Present the 2023 Recipient with the…
SAN DIEGO, June 28, 2023 (GLOBE NEWSWIRE) — Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech…
Former Awardee and Artelo Employee, Professor Saoirse O’Sullivan will Present the 2023 Recipient with the…
Primary Endpoint of Safety and Efficacy Endpoint Both Met with Clinical Activity and Increased Survival…
Primary Endpoint of Safety and Efficacy Endpoint Both Met with Clinical Activity and Increased Survival…
Company intends to submit 510(k) pre-market notification to the FDA NEW YORK, June 28, 2023…
Company intends to submit 510(k) pre-market notification to the FDA NEW YORK, June 28, 2023…
MINNEAPOLIS, June 28, 2023 (GLOBE NEWSWIRE) — Panbela Therapeutics, Inc . (Nasdaq: PBLA), a clinical stage…
MINNEAPOLIS, June 28, 2023 (GLOBE NEWSWIRE) — Panbela Therapeutics, Inc . (Nasdaq: PBLA), a clinical stage…
Dr. Zhong Zhong joins Ovid as Chief Scientific Officer (CSO) and Dr. Manoj Malhotra assumes…
Dr. Zhong Zhong joins Ovid as Chief Scientific Officer (CSO) and Dr. Manoj Malhotra assumes…
Results support comparability of cosibelimab 800 mg every-two-week and 1200 mg every-three-week dosing regimens Biologics…
Results support comparability of cosibelimab 800 mg every-two-week and 1200 mg every-three-week dosing regimens Biologics…
SYDNEY, Australia, June 28, 2023 (GLOBE NEWSWIRE) — Recce Pharmaceuticals Limited (ASX: RCE, FSE: R9Q),…
SYDNEY, Australia, June 28, 2023 (GLOBE NEWSWIRE) — Recce Pharmaceuticals Limited (ASX: RCE, FSE: R9Q),…
Company views that results of comprehensive data analysis of TSHA-120 and development of disease progression…
Company views that results of comprehensive data analysis of TSHA-120 and development of disease progression…
Early data observed from NAVAL-1 in R/R EBV+ PTCL consistent with Phase 1b/2 clinical trial…
Early data observed from NAVAL-1 in R/R EBV+ PTCL consistent with Phase 1b/2 clinical trial…